![](/img/cover-not-exists.png)
Pediatric patients benefit from intravenous busulfan for myeloablation in allogeneic HSCT
V.L. Fisher, M.L. Nieder, C. Malbassi, E.R. Halliday, S.R. Wiersma, M. ReedVolume:
10
Year:
2004
Language:
english
DOI:
10.1016/j.bbmt.2003.12.194
File:
PDF, 60 KB
english, 2004